The government said Switzerland should not lose its edge in pharmacology and bio-technology by banning stem cell research, which provides hopes for the treatment of various diseases, such as paralysis, heart attack, diabetes, Parkinson's disease and Alzheimer's.
Researchers spotted the flaw by scanning and comparing the DNA of individuals with Parkinson's.
Amgen executives and some of the trial investigators met with the FDA in January.
It occurs when there is a loss of cells in a part of the brain that produces dopamine, a neurotransmitter that communicates with other brain cells which regulate motor functions.
